ABSTRACT Introduction Satisfaction with treatments may affect medication adherence and use patterns, including the use of co‐medication. We aimed to compare different medications for allergic rhinitis (AR) on (i) patients' satisfaction and (ii) co‐medication use frequency. Methods We assessed data from the mHealth app MASK‐air. We evaluated days on which users with self‐reported AR had used—alone or in co‐medication—intranasal corticosteroids (INCS), intranasal antihistamines (INAH), fixed combinations of INAH+INCS, or oral antihistamines (OAH). We built multivariable regression models to compare these different AR medication classes (as well as individual medications) on their (i) treatment satisfaction levels (measured using a specific daily visual analogue scale ‘VAS satisfaction’) and (ii) odds of being used in co‐medication. Results We assessed 28,177 days reported by 1691 MASK‐air users. For all medication classes, co‐medication usage was associated with lower treatment satisfaction. When used in monotherapy, OAH were associated with lower VAS satisfaction than INCS (−1.7 points; 95% CI = –2.7; –0.7) or INAH+INCS (−2.1 points; 95% CI = –3.5; –0.7). INCS displayed higher odds of being used in co‐medication than OAH (OR = 1.3; 95% CI = 1.0; 1.6) or INAH+INCS (OR = 1.3; 95% CI = 0.8; 1.8). When comparing individual intranasal medications, fluticasone furoate and fluticasone propionate tended to be more frequently used in co‐medication. Among individual OAH, desloratadine and rupatadine were associated with higher satisfaction, while fexofenadine was more frequently used in co‐medication. Conclusion Using patient‐reported data, we evaluated different medication classes and treatments in terms of satisfaction and co‐medication frequency. These results provide key insights into the acceptability of AR treatments and will contribute to future treatment guidelines.
Sousa‐Pinto et al. (Fri,) studied this question.